NCT07320963 2026-03-20
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1/2 Not yet recruiting
Clinical Trials
14 trialsNCT06970145 2025-11-18
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Nanfang Hospital, Southern Medical University
Phase 1/2 Recruiting
NCT07139470 2025-08-24
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Not yet recruiting
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT04165330 2025-02-24
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Phase 1/2 Active not recruiting
NCT04770688 2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2 Completed
NCT05816499 2024-06-17
AK104IIT018
Shanghai Chest Hospital
Phase 1/2 Active not recruiting
NCT06456138 2024-06-13
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT04803851 2023-06-22
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04507906 2022-06-28
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC
Shanghai Chest Hospital
Phase 1/2 Completed
NCT03706287 2020-04-06
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown
NCT04157491 2019-11-08
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT04004975 2019-07-02
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
Shandong Cancer Hospital and Institute
Phase 1/2 Unknown
NCT03416517 2019-02-15
Anlotinib and Irinotecan for Ewing Sarcoma
Peking University People's Hospital
Phase 1/2 Unknown